Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Recent COPD Exacerbation Did Not Affect Aclidinium’s Efficacy in High-Risk Patients

Publish date:: November 6, 2019

Key clinical point: A history of recent exacerbations didn’t significantly affect the safety or efficacy of aclidinium bromide in patients with moderate to severe COPD and high cardiovascular risk.

Major finding: Risk of major adverse cardiac events with aclidinium treatment was not increased vs placebo, irrespective of whether patients had exacerbations in the prior year (interaction P = .233).

Study details: Subgroup analysis of the phase IV ASCENT-COPD study including 3,530 patients with COPD at high cardiovascular risk.

Disclosures: Dr. Wise provided disclosures related to AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Sunovion, Mylan/Theravance, ContraFect, Pearl, Merck, Verona, Novartis, AbbVie, Syneos, Regeneron, and Kiniksa.

Citation:

Wise R et al. CHEST 2019. Abstract, doi: 10.1016/j.chest.2019.08.231.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Pulmonology

Does daily inhaler monitoring improve asthma outcomes in children?,

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

E-cigarette use tied to increased COPD, asthma risk,

Obesity, hypoxia predict severity in children with COVID-19,

Telehealth finds acceptance among patients with CF, clinicians,